Involved Site Radiation Therapy
Sponsors
Memorial Sloan Kettering Cancer Center, New York Medical College, Zhongshan Ophthalmic Center, Sun Yat-sen University
Conditions
Hodgkin LymphomaNon-hodgkin LymphomaPrimary Ocular Adnexal MALT Lymphoma
Phase 2
Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma
Active, not recruitingNCT03179917
Start: 2017-06-08End: 2027-06-01Updated: 2026-09-02
Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma
RecruitingNCT05253495
Start: 2022-02-01End: 2028-06-30Target: 80Updated: 2025-06-13
Unknown Phase
RCT of Intralesional Rituximab Injection Versus Involved Site Radiation Therapy in Ocular Adnexal MALT Lymphoma
Not yet recruitingNCT06064344
Start: 2023-10-07End: 2027-10-06Target: 108Updated: 2023-10-03
RCT on Intralesional Rituximab Injection Versus ISRT in Ocular Adnexal MALT Lymphoma
RecruitingNCT06190301
Start: 2023-12-20End: 2029-12-31Target: 108Updated: 2026-04-20